These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7886530)

  • 1. Long-term survival after autologous bone marrow transplantation for metastatic breast carcinoma.
    Saez RA; Slease RB; Selby GB; Strnad C; Epstein RB; Confer DL
    South Med J; 1995 Mar; 88(3):320-6. PubMed ID: 7886530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
    Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
    J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
    Crump M; Goss PE; Prince M; Girouard C
    J Clin Oncol; 1996 Jan; 14(1):66-9. PubMed ID: 8558222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.
    Humblet Y; Symann M; Bosly A; Delaunois L; Francis C; Machiels J; Beauduin M; Doyen C; Weynants P; Longueville J
    J Clin Oncol; 1987 Dec; 5(12):1864-73. PubMed ID: 2824708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow transplantation for metastatic breast cancer.
    Saez RA; Selby GB; Slease RB; Epstein RB; Mandanas RA; Confer DL
    J Okla State Med Assoc; 1994 Sep; 87(9):405-10. PubMed ID: 7996314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
    Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
    J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
    Ueno NT; Rondón G; Mirza NQ; Geisler DK; Anderlini P; Giralt SA; Andersson BS; Claxton DF; Gajewski JL; Khouri IF; Körbling M; Mehra RC; Przepiorka D; Rahman Z; Samuels BI; van Besien K; Hortobagyi GN; Champlin RE
    J Clin Oncol; 1998 Mar; 16(3):986-93. PubMed ID: 9508181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
    Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
    Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Meisenberg B; Marks LB; Winer E; Kurtzberg J; Bast RC; Jones R; Shpall E
    J Clin Oncol; 1993 Jun; 11(6):1132-43. PubMed ID: 8501500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
    Purdy MH
    Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
    Vredenburgh JJ; Coniglio D; Broadwater G; Jones RB; Ross M; Shpall EJ; Hussein A; Rizzieri D; Marks LB; Gilbert C; Affronti ML; Moore S; McDonald C; Petros WP; Peters WP
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):195-203. PubMed ID: 16443517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
    Spitzer G; Farha P; Valdivieso M; Dicke K; Zander A; Vellekoop L; Murphy WK; Dhingra HM; Umsawasdi T; Chiuten D
    J Clin Oncol; 1986 Jan; 4(1):4-13. PubMed ID: 3510281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
    Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD
    Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer.
    Kalaycioglu ME; Lichtin AE; Andresen SW; Tuason L; Bolwell BJ
    Am J Clin Oncol; 1995 Dec; 18(6):491-4. PubMed ID: 8526191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.
    Baker WJ; Vukelja SJ; Burrell LM; Lee N; Perry JJ
    Bone Marrow Transplant; 1998 Apr; 21(8):775-8. PubMed ID: 9603400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.